An observational study in Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States — 7 open to participants now, 16 under way, 5 of them phase 3. Gastro-enteropancreatic neuroendocrine tumor · United States.
Among the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States, this one is the only one that started in 2026, is one of 8 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 30th registered.
73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.
Browse Gastro-enteropancreatic neuroendocrine tumor studies →7 of the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States are open now. Recruiting first, the newest first:
RayzeBio, Inc. · Sites in United States, Canada
Ages 18+
Emory University · Sites in United States
Ages 18+
ITM Solucin GmbH · Sites in United States, France, Spain
Ages 24 mo–18 yrs
Novartis Pharmaceuticals · Sites in United States, Canada, China and 9 more countries
Ages 12–100
Methodist Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Gastro-enteropancreatic neuroendocrine tumor studies recruiting now, 13 (62%) set no upper age limit and 4 (19%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 5
First in 2011; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,023 is above the median of 164 across 21 observational studies indexed under Gastro-enteropancreatic neuroendocrine tumor.
Median enrollment 21 across the 22 interventional studies, 75 across the 8 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
Novartis has 7 studies filed under Gastro-enteropancreatic neuroendocrine tumor — fewer than ten, so there is no comparison to draw.
6 of the studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05050942Phase 3Camurus ABA Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | 2026-11 |
| NCT05477576Phase 3RayzeBio, Inc.Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | 2026-12 |
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT04609592Stanford UniversityStudy of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | 2026-11 |
| NCT07165132RayzeBio, Inc.Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
Patients with evidence of a GEP-NET diagnosis between 01 January 2018 and 31 December 2025 and initiating a 1L treatment during this time period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with ≥12 months (360 days) of continuous data availability (proxy for continuous health plan enrollment) prior to the index date, defined as:
Patients with ≥1 month (30 days) of continuous data availability (proxy for continuous health plan enrollment) following the index date, defined as:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients newly diagnosed with a GEP-NET between 01 January 2018 and 31 December 2025.
A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L lutetium Lu 177 dotatate.
A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L CAPTEM.
A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L cabozantinib.
A subgroup of the Overall GEP-NET Cohort. Patients receiving lutetium Lu 177 dotatate in 2L or later settings.
A subgroup of the Overall GEP-NET Cohort. Patients receiving CAPTEM in 2L or later settings.
A subgroup of the Overall GEP-NET Cohort. Patients receiving cabozantinib in 2L or later settings.
This study also gives Cabozantinib. No intervention listed here names it: that was found by reading the record.
Number of Lines of Therapy (LOTs)
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Treatment Regimen per LOT
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Type of Therapy in Each LOT
Time frame: Up to approximately 8 years
Number and Percentage of Patients who Discontinue all Medications Within the 1L Treatment Regimen
Time frame: Up to approximately 8 years
Number of Cycles of Medications Within the Treatment Regimen Before Discontinuation
Time frame: Up to approximately 8 years
Time to 1L Treatment Discontinuation
Time frame: Up to approximately 8 years
Duration Between GEP-NET Diagnosis and 1L Treatment
Time frame: Baseline
Number and Percentage of Patients who Switch Treatment From 1L to Fifth-line (5L) Treatment
Time frame: Up to approximately 8 years
Number and Percentage of Patients With Addition of Other Therapies While on Initial 1L Therapy
Time frame: Up to approximately 8 years
Time to Next Treatment (TTNT)
Time frame: Up to approximately 8 years
Overall Survival (OS)
OS calculated as the number of weeks from the start of treatment until death.
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Demographics
Demographics include: * Age group (18-34, 35-44, 45-54, 55-64, 65+ years) * Sex * Geographic region * Payer type * Race/ethnicity * Education level * Occupation * Marital status
Time frame: Baseline
Age
Time frame: Baseline
Duration of Follow-up
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Clinical Characteristics
Clinical characteristics include: * National Cancer Institute (NCI) comorbidity index category (0, 1, 2, 3+) * Comorbidities * Treating provider specialty * Metastatic sites (bone, visceral, lymph node, liver) * Number of distinct metastatic sites (0, 1, 2, 3, 4+)
Time frame: Baseline
NCI Comorbidity Index Score
The NCI comorbidity index is a tool used to measure the risk of non-cancer deaths for cancer patients based on the presence and severity of other health conditions. It includes 14 conditions identified using administrative data diagnosis and procedure codes. The index excludes solid tumors, leukemias, and lymphomas as comorbid conditions. Each condition is assigned a score (from 1 to 6) based on how serious it is and patient scores are summed to give a final overall score. A high score indicates a higher burden of comorbid conditions and possible higher risk of death.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Feb 2027 → Jun 2027 and completion Feb 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gastro-enteropancreatic neuroendocrine tumor →